A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Everolimus (Primary) ; Aromatase inhibitors
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.